Definitive conformal radiotherapy for localized high-risk prostate cancer: A long-term follow-up study with PSA course

Anticancer Research

Volumn 27, Issue 4 A, 2007, Pages 1847-1851

  Bruns, Frank ^a   Franzki, Cordula ^a   Wegener, Gerd ^a   Karstens, Johann H ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Androgen deprivation; Conformal radiotherapy; High risk; Prostate cancer; PSA; Short term

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; CANCER CLASSIFICATION; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROSTATE CANCER;

ANDROGEN ANTAGONISTS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIERS ESTIMATE; LONGITUDINAL STUDIES; MALE; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY, CONFORMAL; RISK FACTORS;

EID: 34250730675     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (22)

1. Fischer K, Loertzer H and Fornara P: The use of complexed PSA for the early detection of prostate cancer. Anticancer Res 25: 1591-1596, 2005.
2. Ludwig JA and Weinstein JN: Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 5: 845-856, 2005.
3. Pollack A, Zagars GK and Kopplin S: Radiotherapy and androgen ablation for clinically localized high-risk prostate cancer. Int J Radiat Oncol Biol Phys 32: 13-20, 1995.
4. Roach M 3rd, Lu J, Pilepich MV, Asbell SO, Mohiuddin M, Terry R, Grignon D, Lawton C, Shipley W and Cox J: Predicting long-term survival and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials. Int J Radiat Oncol Biol Phys 47: 617-627, 2000.
5. D'Amico AV, Chen MH, Oh-Ung J, Renshaw AA, Cote K, Loffredo M and Richie JP: Changing prostate-specific antigen outcome after surgery or radiotherapy for localized prostate cancer during the prostate-specific antigen era. Int J Radiat Oncol Biol Phys 54: 436-441, 2002.
6. Chism DB, Hanlon AL, Horwitz EM, Feigenberg SJ and Pollack A: A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy. Int J Radiat Oncol Biol Phys 59: 380-385, 2004.
7. International Union Against Cancer (UICC): Prostate (ICD-O C61). In: TNM classification of malignant tumors. Fifth edition. Sobin LH and Wittekind Ch (eds.). NewYork, Wiley-Liss Inc. pp. 170-173, 1997.
8. The American Society for Therapeutic Radiology and Oncology Consensus Panel and Cox JD: Consensus Statement: Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 37: 1035-1041, 1997.
9. Zietman AL, Coen JJ, Shipley WU, Willett CG and Efird JT: Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome. J Urol 151: 640-645, 1994.
10. Lee WR, Hanks GE, Schultheiss TE, Corn BW and Hunt MA: Localized prostate cancer treated by external-beam radiotherapy alone: serum prostate-specific antigen-driven outcome analysis. J Clin Oncol 13: 464-469, 1995.
11. Partin AW, Pound CR, Clemens JQ, Epstein JI and Walsh PC: Serum PSA after anatomic radical prostatectomy. The John Hopkins experience after 10 years. Urol Clin N Amer 20: 713-725, 1993.
12. Hanks GE, Perez CA, Kozar M, Asbell SO, Pilepich MV and Pajak TF: PSA confirmation of cure at 10 years of T1b, T2, N0, M0 prostate cancer patients treated in RTOG Protocol 7706 with external beam irradiation. Int J Radiat Oncol Biol Phys 30: 289-292, 1994.
13. Lee WR, Hanlon AL and Hanks GE: Prostate-specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: The relationship between nadir level and disease free survival. J Urol 156: 450-453, 1996.
14. European Group on Tumour Markers (EGTM): Tumour markers in prostate cancer - EGTM recommendations. Anticancer Res 19: 2799-2802, 1999.
15. Lawton CA, Winter K, Murray K, Machtay M, Mesic JB, Hanks GE, Coughlin CT and Pilepich MV: Updated results of the phase III RTOG trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 49: 937-946, 2001.
16. Damber JE: Endocrine therapy for prostate cancer. Acta Oncologica 44: 605-609, 2005.
17. Kupelian PA, Mohan DS, Lyons J, Klein EA and Raddy CA: Higher than standard radiation doses (> or =72 Gy) with or without androgen deprivation in the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys 46: 567-574, 2000.
18. Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B, Hug EB, Asbell SO and Grignon D: Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma: long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 61: 1285-1290, 2005.
19. Pilepich MV, Winter K, John MJ, Mesic JB, Sause W, Rubin P, Lawton C, Machtay M and Grignon D: Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50: 1243-1252, 2001.
20. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Mattelaer J, Lopez Torecilla J, Pfeffer JR, Lino Cutajar C, Zurlo A and Pierart M: Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomized trial. Lancet 360: 103-106, 2002.
21. Hanks GE, Pajak TF, Porter A, Grignon D, Brereton H, Venkatesan V, Horwitz EM, Lawton C, Rosenthal SA, Sandler HM and Shipley WU: Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 21: 3972-3978, 2003.
22. Zapatero A, Valcarcel F, Calvo FA, Algas R, Bejar A, Maldonado J and Villa S: Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study. J Clin Oncol 23: 6561-6568, 2005.